Semaglutide improved measures of heart filling in rats and minipigs with obesity-related heart failure without a significant difference in body weight. Cedars-Sinai announced the preclinical findings on October 13. The experiments offer evidence of heart effects beyond substantial weight loss, while leaving the mechanism and any lower-dose benefit in people unresolved.[1][4]
Buy 1, Get 1 20% Off
Pick any two research compounds. Take 20% off the lower priced one.
Applied automatically at checkout, no code needed
Claim my 20% off →In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.
Research analysis. The new findings are from animal models, not a trial of a lower-dose treatment in people.
A heart can pump well and still struggle to fill
Heart failure with preserved ejection fraction, or HFpEF, describes a problem that a normal-looking pumping percentage can miss. The heart may eject a preserved proportion of the blood in its main pumping chamber while that chamber has difficulty relaxing and filling. In the obesity-associated form examined here, enlarged heart muscle, scarring and fat accumulation can accompany that difficulty.[1]
That makes filling pressure a useful measurement. A stiff ventricle can require more pressure to fill, even when its ejection fraction remains preserved. The study's main endpoint was left ventricular end-diastolic pressure: pressure inside that chamber at the end of filling.[1]
The paper appeared in the European Heart Journal on October 5. The October 13 announcement brought its animal findings to a wider audience; it did not announce a new human trial. The experiments asked whether semaglutide could change the diseased heart under conditions chosen to avoid substantial weight loss.[1][4]
What changed in the rats and minipigs
Researchers randomly assigned male ZSF1 obese rats to semaglutide or vehicle, the comparison solution without the drug, for 16 weeks. Each group contained 12 animals. Investigators assessing heart function and tissue samples were blinded to the assignments.[1]
At the end of treatment, mean filling pressure was 13.2 mmHg with semaglutide and 30.2 mmHg with vehicle, a between-group difference of 17 mmHg. The reported standard errors were 1.3 and 1.1 mmHg, respectively, with P below 0.0001. The lower pressure indicates that the treated hearts could fill under less pressure at that assessment.[1]
The treated rats continued gaining weight, and the study found no significant treatment-related difference in body weight. Their heart tissue nevertheless showed less interstitial fibrosis, the scarring between cells. Those tissue measurements used six animals per group; a separate analysis of muscle-fiber relaxation used four animals per group. The smaller samples matter when judging how broadly the detailed mechanism has been tested.[1]
A second experiment used female Göttingen minipigs with an induced combination of hypertension and diet-related metabolic disease. After eight weeks of disease induction, five animals per group received semaglutide or control treatment for 12 weeks. Heart filling measurements, enlargement and fibrosis improved with semaglutide while body weight did not significantly change.[1]
Agreement across the two species makes the finding more informative than one rodent experiment alone. Both models, however, represented obesity-associated cardiometabolic HFpEF. They cannot stand in for every form of a condition that also occurs with aging, kidney disease and other illnesses.[1]
Stable body weight can conceal changes inside an organ
The scale records total mass. It cannot show where fat is stored or how heart muscle handles fuel. In tissue collected after the 12-week minipig treatment, microscopy showed fewer and smaller lipid droplets in the heart, alongside reduced fibrosis. These observations connect the filling-pressure result to changes within the organ rather than to a large change in total body size.[1]
This distinction also limits the phrase weight independent. A nonsignificant weight difference is not proof that the groups were identical in every metabolic respect. Food intake was not formally measured, and changes in glucose handling, circulating lipids or fat distribution could have contributed to the heart findings.[1]
Nor did the researchers directly demonstrate that semaglutide activated GLP-1 receptors in heart or liver tissue. The molecular analyses found downstream changes associated with treatment, but receptor binding or receptor-blocking experiments were not performed. The evidence supports effects beyond a substantial fall in body weight; the route from the drug to those tissue effects remains open.[1]
What the human STEP-HFpEF trial measured
Human evidence answers a different question. The 2023 STEP-HFpEF trial randomly assigned 529 people with HFpEF and obesity to semaglutide or placebo for 52 weeks. It was a phase 3 trial, with 263 participants assigned semaglutide and 266 placebo. Eligibility required a body-mass index of at least 30 and left ventricular ejection fraction of at least 45%.[2][3]
Its two main outcomes were change in body weight and change in the Kansas City Cardiomyopathy Questionnaire clinical summary score. That questionnaire measures heart-failure symptoms and physical limitations on a scale from 0 to 100, with higher scores indicating better health status.[2][3]
At 52 weeks, the score improved by an average of 16.6 points with semaglutide and 8.7 with placebo. The estimated treatment difference was 7.8 points, with a 95% confidence interval from 4.8 to 10.9. Average body weight fell 13.3% and 2.6%, respectively, an estimated difference of 10.7 percentage points.[2]
Patients therefore reported greater improvement in symptoms and limitations while also losing substantially more weight. The randomized comparison establishes the effect of the treatment strategy. It does not isolate what the symptom benefit would have been if the weight change had been held equal.[2][3]
Safety is a separate comparison
The trial's posted safety results cover baseline through week 57, separately from the week-52 efficacy endpoints. The safety population included all 263 semaglutide recipients and 266 placebo recipients who received at least one dose. The registry defines the presented adverse events as treatment emergent, with onset during its on-treatment period. That period excludes intervals with five or more consecutive missed weekly doses.[3]
Within that safety reporting framework, serious adverse events affected 35 of 263 semaglutide participants and 71 of 266 placebo participants. Non-serious nausea affected 45 of 263 and 7 of 266, respectively. These categories answer different questions: a lower total of serious events does not mean that treatment caused no troublesome side effects.[3]
Neither that human safety comparison nor the animal experiment establishes that a lower human dose would retain the same benefit with fewer adverse effects. The animal exposures were selected for the response in each species, and the paper says they cannot be translated into a specific clinical dose.[1][3]
The next study needs to separate exposure from weight change
The animal study received public and nonprofit support, including National Institutes of Health grants. Its disclosures include Gordian Biotechnology employees among the authors and consulting relationships with drugmakers, including Novo Nordisk, for one author. Eikonizo Therapeutics sponsored an assay used in the work. Novo Nordisk funded STEP-HFpEF.[1][2]
The useful next step is to establish how the animal exposures relate to human exposure, then test a clinical strategy for patient benefit and tolerability. Direct receptor studies could separately determine whether the heart is responding locally or through metabolic changes elsewhere.[1] The semaglutide kidney biopsy trial illustrates another setting in which tissue findings and a trial's main endpoints need separate interpretation.
For now, the animal work gives researchers a concrete reason to look beyond the weighing scale. A human trial that separates exposure, weight change and heart outcomes would show whether that distinction can improve treatment, rather than simply explain another laboratory result.[1]
Frequently asked questions
Does a preserved ejection fraction mean the heart is normal?
No. Ejection fraction describes the proportion of blood pumped out of the ventricle. HFpEF can involve impaired relaxation and high filling pressure even when that proportion is preserved. The animal experiments measured filling and tissue changes as well as pumping function.
Did the animal study compare a lower exposure with a weight-loss exposure?
No. It compared the selected semaglutide exposures with controls. The paper identifies the absence of a direct comparison with weight-loss-promoting regimens as a limitation, so it cannot establish that the two approaches are equivalent.
Sources and further reading
Related reading
Buy 1, Get 1 20% Off
Pick any two research compounds. Take 20% off the lower priced one.
Applied automatically at checkout, no code needed
Claim my 20% off →In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.